Bruno Tocque, President of the Management Board of ExonHit said "We are delighted to initiate our Phase 2 clinical trial for EHT 0202. We also aim, through that study, to further illustrate the clinical utility of our blood-based diagnostic for Alzheimer's disease. This milestone reflects ExonHit's strategy, which is to provide therapeutic and diagnostic solutions in chronic diseases such as Alzheimer's disease".
About ExonHit Therapeutics
ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.
ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer's disease or atherosclerosis.
In parallel, ExonHit is developing its own therapeutic pipeline in the
field of neurodegenerative diseases and cancer. The Company has advanced
drug candidates into
|SOURCE ExonHit Therapeutics SA|
Copyright©2007 PR Newswire.
All rights reserved